Introduction
Human placental/umbilical cord blood (CB), as a source of hematopoietic progenitor cells for bone marrow (BM) reconstitution, has been shown to yield successful transplants from siblings [1] [2] [3] and more recently from unrelated donors. 4, 5 In comparison with BM, the collection of CB is easier and the transmission of certain infectious agents, particularly cytomegalovirus, to recipients, is much less common. 5 Most importantly, CB graft may result in decreased incidence of acut graft-versus-host disease (GVHD) even in partially mismatched cases. 3, 4 The most important potential disadvantage of CB is the limited nucleated cell content of donation (a mean of 117 mls ± 17 s.d. and a mean of 15.6 × 10 9 /l ± 10.3 nucleated cells). 5, 6 Since the first CB transplantation in 1988 2 the number of transplantations with CB hematopoietic cells is increasing and nowadays more than 200 have performed worldwide. There is wide international agreement that a pilot clinical CB transplant study is required to evaluate results in comparison with related and unrelated marrow donor transplants. Within the framework of this program the Eurocord Transplant Group was established with the purpose of studying the properties of hematopoietic stem cells present in placental blood at birth for clinical use in patients affected predominantly by hematological diseases. 
Quantity and quality of immature hematopoietic stem cells from cord blood
The use of human cord blood as source of transplantable hematopoietic stem and progenitor cells began with a multi-institutional laboratory study. 1, 7 A common approach to assess the quality of stem cell grafts relies on methylcellulose-based colony assays for lineage-committed hematopoietic progenitor cells as colony-forming units granulocyte/macrophage (CFU-GM). 7, 8 Besides the different culture systems immunofluorescence and flow cytometry can be regarded as a reliable and rapid method for detection of early stem/progenitor cells. The CD34 antigen is of particular interest because it represents the only cell-surface antigen identified by monoclonal antibodies (MoAb), whose expression within the hematopoietic system is restricted to primitive progenitor cells of all lineages. 9 According to the previous reports, 1,2 cord blood represents a rich source of hematopoietic stem/progenitor cells, but CD34
+ cell enumeration was not reported for these studies. However, Broxmeyer and co-workers 10 have confirmed that the single primitive CD34-positive human umbilical cord blood hematopoietic progenitors have a very high proliferative and replating potential and may at least in part be associated with the successful hematopoietic repopulating capacity of umbilical cord blood cells.
Several groups have recently analyzed the CD34 + cells present in the different cell sources used for transplantation including human CB. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] These data indicate that using only one-color CD34 analysis may not provide sufficient information, 12, 15 but sensitive detection and enumeration of CD34 + cells is required. 12, 13, 15 The widespread use of CD34 expression as a measure of the transplant potential of hematopoietic tissue also means that it is important to establish any antibody-or tissue-related differences in levels of expression.
14 As a result of the different levels of detection by different MoAbs, the apparent number of CD34 + cells vary by approximately six-fold.
14 Furthermore, the kinetics of the engraftment seems to be depending on the composition of CD34 subpopulations, eg the distribution of the early and late myeloid and B-lymphoid progenitor cells. 15, 17 A novel developed in vivo functional assay for primitive human hematopoietic cells is based on their ability to repopulate the BM of severe combined immunodeficient (SCID) and non-obese diabetic/SCID (NOD/SCID) mice. 18 These results also confirm that CB is enriched for the primitive hematopoietic cells compared with BM or mobilized PB, an observation that has important implications for clinical transplantation and stem cell expansion strategies.
Engraftment will depend not only on the number of progenitors, but also on the quality of these cells for proliferation and self-renewal. These qualities of stem and progenitor cells appear to be high. It has been demonstrated that committed hematopoietic progenitor cells are at least as numerous in cord blood as in normal BM. 13, 15, 16 Cord blood cells can be extensively expanded in suspension culture with different combinations of cytokines, 20 as well as in NOD/SCID mice 17 and other murine model in vivo. 21 Thus, immature hematopoietic stem cells and progenitor cells appear to be of good quality in cord blood. 16 
Immune cells in cord blood
There has been little or no GVHD detected in children receiving HLA-matched or one antigen mismatched sibling cord blood, 2, 3, 7, 16, 22 and results using unrelated CB have been similar. 4, 5, 16 There is evidence that immune cells from CB react differently to those in adults. Monocyte/macrophage and Tand B-lymphocytes are the major immune response cells. It has been reported that a low antigen presenting ability found in CB monocyte/macrophage is due to their immaturity. 16, 23 
Immunologic characterization of cord blood B-lymphocytes
It is known that newborn B cells are capable of producing amounts of IgM antibody comparable with those of adult B cells, but their capacity to produce IgG or IgA is remarkably reduced. 24 In humans, during fetal development the B cell populations show distinct phenotypes at different tissue sites. Besides conventional B cells (CD20 + , CD24
− ) in fetal liver and bone marrow a significant fraction of fetal splenocytes are CD5
+ B-lymphocytes. 25 At birth, most IgM + human umbilical cord blood B-lymphocytes co-express the CD5 antigen, too. 26 Gluckman et al published that 68% of the CD19 + cord blood B-lymphocytes proved to be CD5 antigen positive. 27 CD5 + B-lymphocytes share many properties of Ly-1 murine B cells including self-replenishment and feedback regulation of development. This unique population of B cells (CD5 + B cells) is known as B1a lymphocytes preferentially generated from fetal/neonatal sources of progenitors. Functionally, the antibodies produced by B1a cells are characterized by the predominance of IgM, minimal hypermutation and high frequency of low affinity, polyreactive, self-reactive specificities. 28 Our special interest was characterizing the CB B-lymphocytes studying differential expression of B cell-associated antigens on CD5 + B cells (B1a) and CD5 − B cells (B1b) using MoAb panel from the 6th International Workshop on Human Differentiation Antigens (Kobe, 1996) . 29, 30 Based on our recent results, cord blood CD5 + B cells are expressing CD19, CD20, CD22, CD24, HLA-DR pan-B and CD32, CD39, CD76, CD79, CD137, sIgM and CD9 B-subpopulation antigens. 29, 30 According to their immunophenotype the cord blood B1a cells can be regarded as CD5 
Immunologic characterization of cord blood T-lymphocytes and NK cells Number and phenotype of cord blood T-lymphocytes:
In cord blood, about 50% of low density mononuclear cells express CD3, compared to 70% in adult blood. 13, 16, 22, 26, [31] [32] [33] However, phenotypic analysis of T cell subsets (CD4, CD8) revealed no significant difference between adult and cord blood. Newborn T cells have lower level of both IL-2 receptors and HLA-DR than do adult T cells. The CD4 + T cells represents 31% of lymphocytes with a great prevalence of the CD4
+ populations. 16 
Function of the T-lymphocytes in cord blood:
It is of interest that little cytotoxic T cell activity is generated by cord blood cells even after primary, secondary and tertiary stimulation by allogeneic cells. 10, 13, 16, 31, 34 The maximal responses observed in CB T cells were much less than those of adult T cells, whereas the Con-A-induced proliferative responses of these cells showed no significant differences. The decreased responses of CB T cells were due to their lower efficiency in activating the cellular events in T cell activation and proliferation phase. Cord blood T cells have significantly less ability than adult T cells to produce IL-2 and express functional IL-2R complexes, especially high-affinity IL-2R complexes, and HLA-DR. These functional characteristics may be related to the immaturity of cord blood T cells.
Results obtained from our own experiments also indicate a distinct cytokine production profile in CB cells as compared with PB. 13, 30 A reduction was observed in the potential of CB cells to produce the Th-1 cell-derived cytokines, IFN␥ and IL-2 upon stimulation with PHA or allogeneic cells. On the contrary, a slight increase was found in the production of IL-6 by alloactivated CB cells. The reduction of IFN␥ and IL-2 could be associated with the presence of immature, naive T cells in CB.
Cord blood natural killer (NK) cells:
Cord blood NK cells are CD3 −
CD56
+ cells expressing CD2, CD7, C11a-c, CD18, CD38, CD45RA and p75 IL-2 receptor. 13, 26, 35 Only small amounts of CD3 +
CD16
+ cells exist in CB. 13, 26, 35 Cord blood NK cell activity is low or similar to that in adult blood but lymphokine activated killer cell activity is readily induced in CB by cytokines such as IL-2 or IL-12. 35, 36 In summary, umbilical cord blood stem cells are an alternative source of transplantable cells that can be used to reconstitute hematopoiesis in children with malignant and non-malignant diseases after treatment with myeloablative doses of chemotherapy. The higher frequency of repopulating cells in CB compared with adult tissues suggests that CB may be better source of stem cells both for transplantation and ex vivo manipulations, such as retroviral infection and gene therapy or stem cell expansion. To establish a cryopreserved human CB bank of unrelated donors for clinical transplantation is important.
